Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058758 · ClinicalTrials.gov registry record
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 80
- Enrollment target
NCT02058758 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 80 participants.
The verdict
NCT02058758 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high sensitivity because the intravenous MR contrast agent highlights regions with increased vascularization and vascular permeability compared to normal breast tissues and benign lesions.
Interventions
- DEVICE Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2019-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058758
The ClinicalTrials.gov registry entry for NCT02058758 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.
NCT02058758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02058758 about?
NCT02058758 is a clinical study titled "Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer". Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high sensitivity because the intravenous MR contrast agent highlights regions with increased vascularization and vascular pe...
What is the current status of trial NCT02058758?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2014-03-01. Estimated completion is 2019-09-01.
What interventions are being tested in trial NCT02058758?
The interventions under investigation include: Magnetic Resonance Imaging (DEVICE).
Who is sponsoring clinical trial NCT02058758?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.